Market Overview:
The global postmenopausal vaginal atrophy drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of postmenopausal vaginal atrophy, rising awareness about available treatment options, and growing demand for novel therapies. Based on type, the global postmenopausal vaginal atrophy drugs market is segmented into estrogens and non-estrogens. The estrogens segment is further divided into conjugated equine estrogen (Premarin), esterified estrogens (Menest), ethinyl estradiol (Estrostep FE), and 17β-estradiol (Estrace). The non-estrogen segment includes tibolone (Livial) and raloxifene hydrochloride (Evista). Based on application, the market is classified into vaginal gels, creams, tablets/pills, rings/patches, and others. Geographically, the global postmenopausal vaginal atrophy drugs market is analyzed across North America, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa .
Product Definition:
Postmenopausal vaginal atrophy drugs are used to treat the symptoms of postmenopausal vaginal atrophy, which include dryness, itching, burning, and pain during sex. These drugs help to increase moisture in the vagina and can improve sexual function.
Premarin:
Premarin is a form of estrogen used in the treatment of atrophic vaginitis. It works by increasing the growth of tissues in the vaginal area. Estrogen replacement therapy after menopause or during postmenopausal years helps in improving symptoms such as hot flashes, mood disorders, and others. However, excess usage can lead to serious health issues such as breast cancer and heart diseases.
Vagifem:
Vagifem is a drug that is used to treat atrophic vaginitis. It works by increasing blood flow to the vaginal area and may also help in other symptoms such as dryness, burning, pain during intercourse, thinning of vaginal walls etc. The drug has been approved for use in Europe and Canada but not in the U.
Application Insights:
Vaginal atrophy is a common condition in postmenopausal women. The prevalence of the disease is estimated to be around 5% to 10% among women aged 45 years and above. According to researchers, this condition may affect as many as 1 in 3 postmenopausal women globally.
The global market for PPVAD by application was dominated by vaginal tablets, which accounted for over 40% of the total revenue share in 2017 due primarily to its high convenience and effectiveness compared with other forms such as creams or rings that are applied inside the vagina.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure, high awareness levels among women regarding menopausal symptoms and drug therapy, and availability of a wide range of branded drugs are some factors attributing to its large share. In addition, increasing R&D activities by major players for development of novel menopausal drugs is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population in this region coupled with growing disposable income resulting into increased usage rates for modern therapeutics such as postmenopausal vaginal atrophy drugs. Moreover, government initiatives encouraging health conscious people from developing countries such as India and China are likely contributing toward regional growth.
Growth Factors:
- Increasing awareness about the condition and its treatment options among postmenopausal women.
- Growing demand for effective and safe therapies for treating postmenopausal vaginal atrophy.
- Rising incidence of postmenopausal vaginal atrophy due to increasing life expectancy of women worldwide.
- Availability of novel Postmenopausal Vaginal Atrophy Drugs therapies in the market.
- Increasing research and development activities focused on the development of new Postmenopausal Vaginal Atrophy Drugs therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Postmenopausal Vaginal Atrophy Drugs Market Research Report
By Type
Premarin, Vagifem, Estrace, Estring, Femring
By Application
Vaginal Gels, Creams, Tablets, Rings, Patches
By Companies
Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Allergan plc, Shionogi & Co. Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Postmenopausal Vaginal Atrophy Drugs Market Report Segments:
The global Postmenopausal Vaginal Atrophy Drugs market is segmented on the basis of:
Types
Premarin, Vagifem, Estrace, Estring, Femring
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Vaginal Gels, Creams, Tablets, Rings, Patches
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Actavis plc
- Bionovo, Inc.
- Endoceutics, Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceuticals Ltd.
- Therapeutics MD, Inc.
- Shionogi & Company
- Allergan plc
- Shionogi & Co. Ltd.
Highlights of The Postmenopausal Vaginal Atrophy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Premarin
- Vagifem
- Estrace
- Estring
- Femring
- By Application:
- Vaginal Gels
- Creams
- Tablets
- Rings
- Patches
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Postmenopausal Vaginal Atrophy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Postmenopausal vaginal atrophy drugs are medications that help to improve the symptoms of postmenopausal vaginal atrophy. These drugs can help to improve the size and shape of the vagina, as well as reduce inflammation and pain associated with postmenopausal vaginal atrophy.
Some of the major companies in the postmenopausal vaginal atrophy drugs market are Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Allergan plc, Shionogi & Co. Ltd..
The postmenopausal vaginal atrophy drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Postmenopausal Vaginal Atrophy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Postmenopausal Vaginal Atrophy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Postmenopausal Vaginal Atrophy Drugs Market - Supply Chain
4.5. Global Postmenopausal Vaginal Atrophy Drugs Market Forecast
4.5.1. Postmenopausal Vaginal Atrophy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Postmenopausal Vaginal Atrophy Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Postmenopausal Vaginal Atrophy Drugs Market Absolute $ Opportunity
5. Global Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
5.3.1. Premarin
5.3.2. Vagifem
5.3.3. Estrace
5.3.4. Estring
5.3.5. Femring
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
6.3.1. Vaginal Gels
6.3.2. Creams
6.3.3. Tablets
6.3.4. Rings
6.3.5. Patches
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Postmenopausal Vaginal Atrophy Drugs Demand Share Forecast, 2019-2026
9. North America Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
9.4.1. Vaginal Gels
9.4.2. Creams
9.4.3. Tablets
9.4.4. Rings
9.4.5. Patches
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
9.7.1. Premarin
9.7.2. Vagifem
9.7.3. Estrace
9.7.4. Estring
9.7.5. Femring
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Postmenopausal Vaginal Atrophy Drugs Demand Share Forecast, 2019-2026
10. Latin America Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
10.4.1. Vaginal Gels
10.4.2. Creams
10.4.3. Tablets
10.4.4. Rings
10.4.5. Patches
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
10.7.1. Premarin
10.7.2. Vagifem
10.7.3. Estrace
10.7.4. Estring
10.7.5. Femring
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Postmenopausal Vaginal Atrophy Drugs Demand Share Forecast, 2019-2026
11. Europe Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
11.4.1. Vaginal Gels
11.4.2. Creams
11.4.3. Tablets
11.4.4. Rings
11.4.5. Patches
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
11.7.1. Premarin
11.7.2. Vagifem
11.7.3. Estrace
11.7.4. Estring
11.7.5. Femring
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Postmenopausal Vaginal Atrophy Drugs Demand Share, 2019-2026
12. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
12.4.1. Vaginal Gels
12.4.2. Creams
12.4.3. Tablets
12.4.4. Rings
12.4.5. Patches
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
12.7.1. Premarin
12.7.2. Vagifem
12.7.3. Estrace
12.7.4. Estring
12.7.5. Femring
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Demand Share, 2019-2026
13. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Application
13.4.1. Vaginal Gels
13.4.2. Creams
13.4.3. Tablets
13.4.4. Rings
13.4.5. Patches
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Size and Volume Forecast by Type
13.7.1. Premarin
13.7.2. Vagifem
13.7.3. Estrace
13.7.4. Estring
13.7.5. Femring
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Postmenopausal Vaginal Atrophy Drugs Market: Market Share Analysis
14.2. Postmenopausal Vaginal Atrophy Drugs Distributors and Customers
14.3. Postmenopausal Vaginal Atrophy Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Actavis plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bionovo, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Endoceutics, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novo Nordisk A/S
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva Pharmaceuticals Ltd.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Therapeutics MD, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Shionogi & Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Allergan plc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Shionogi & Co. Ltd.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
